Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
Resverlogix Corp
Modality
Small molecule
Development Phase
Phase 1/2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
37Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00768274CT.gov Safety, Pharmacokinetic Study of RVX000222 in Healthy Subjects and Subjects With Low HDL Cholesterol | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Acute Coronary Syndrome
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Apabetalone (this asset) | Resverlogix Corp | P1/2 | CCC · 48 |
| Aspirin | Shanghai CureGene Pharmaceutical Co., Ltd. | P4 | BBB |
| Atorvastatin | Punjab Institute of Cardology | P4 | BB |
| Ticagrelor | Tianjin Institute of Pharmaceutical Research Co., Ltd | P4 | BB |
| Exenatide | Saint Luke's Health System | P4 | BB |
| Clopidogrel | Shanghai CureGene Pharmaceutical Co., Ltd. | P4 | BB |
| Rosuvastatin | Nanjing First Hospital, Nanjing Medical University | P4 | BB |
| Ezetimibe | Punjab Institute of Cardology | P4 | BB |
| Alirocumab | University Medical Centre Ljubljana | P4 | BB |
+26 more in the Acute Coronary Syndrome cohort
Other indications for Apabetalone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Inherited Lipid Metabolism Disorder | — | P1/2 | CCC · 52 |
| Atherosclerosis | — | P1/2 | CCC · 50 |
| Cardiovascular Disorder | — | P1/2 | CCC · 50 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Apabetalone in Acute Coronary Syndrome. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/apabetalone-acute-coronary-syndrome
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →